Protein Kinase C beta

PKC beta encodes two proteins (PKCB1 and PKCBII) generated by alternative splicing of C-terminal exons. It is widely distributed with wide-ranging roles in processes such as B-cell receptor regulation, oxidative stress-induced apoptosis, androgen receptor-dependent transcriptional regulation, insulin signaling, and endothelial cell proliferation.

Also Known As:

PKC beta 1; PKC beta 2; PKC(beta); PKC-beta II; PKCB1; PKCBII; PKCbeta2; Protein Kinase C beta I; Protein Kinase C beta II; Protein Kinase C beta1; Protein Kinase C beta2; Protein Kinase C-beta (II); Protein Kinase C-beta(II); PKC beta II; beta 1, PKC; beta 2, PKC

Networked: 293 relevant articles (16 outcomes, 52 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Tuttle, Katherine R: 7 articles (11/2008 - 09/2003)
2.	King, George L: 6 articles (03/2009 - 01/2002)
3.	Musib, Luna: 5 articles (06/2010 - 09/2006)
4.	Leitges, Michael: 5 articles (07/2009 - 01/2002)
5.	Thornton, Donald: 4 articles (02/2010 - 06/2006)
6.	Gilbert, Richard E: 4 articles (06/2009 - 02/2003)
7.	Kelly, Darren J: 4 articles (06/2009 - 02/2003)
8.	Lahn, Michael: 4 articles (06/2009 - 02/2007)
9.	Zhang, Yuan: 4 articles (06/2009 - 02/2003)
10.	Anderson, Pamela W: 4 articles (09/2007 - 09/2003)

Related Diseases

1.	Diabetic Retinopathy (Retinopathy, Diabetic) 08/01/2009 - "Additional clinical trials that enroll patients with earlier stages of diabetic retinopathy and/or utilizing more sensitive surrogate outcomes over a longer follow-up would likely show clinical success of PKC-beta inhibition for the treatment of the diabetic retinopathy." 01/01/2013 - "The key gene responsible for causing diabetic retinopathy is protein kinase C beta (PKCβ). " 01/01/2004 - "TRANSLATIONAL RESEARCH IN PRACTICE: a PKC-beta inhibitor for diabetic retinopathy" 11/01/2002 - "The development of selective PKC-beta inhibitors enables new pharmacological therapeutical approaches for treatment of diabetic retinopathy. " 01/01/2007 - "Ongoing prospective clinical trials investigate whether the treatment with the specific PKC-beta inhibitor can prevent the progression of diabetic retinopathy and diabetic macular edema."
2.	Diabetic Nephropathies (Diabetic Nephropathy) 09/01/2007 - "Protein kinase C beta inhibition: the promise for treatment of diabetic nephropathy." 06/01/2009 - "Protein kinase C-beta inhibition attenuates the progression of nephropathy in non-diabetic kidney disease." 11/13/2008 - "Protein kinase C-beta inhibition for diabetic kidney disease." 06/01/2008 - "Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications." 04/01/2008 - "PKC-beta is upregulated at the gene expression level in human diabetic nephropathy. "
3.	Neoplasms (Cancer) 12/06/2019 - "hsa_circ_0092306 inhibited tumor suppressor miR-197-3p expression but promoted tumor promotor protein kinase C beta (PRKCB) expression in MKN-45 cells. " 01/01/2019 - "In vivo PKC beta II expression inhibits GBM tumor growth and prolongs mouse survival through inhibition of YAP/TAZ in an orthotopic mouse xenograft model. " 06/01/2015 - "Apoptin interacts with and regulates the activity of protein kinase C beta in cancer cells." 03/01/2010 - "Tumor-mediated inhibition of dendritic cell differentiation is mediated by down regulation of protein kinase C beta II expression." 07/01/2009 - "IHC done on human TCC samples from a microarray showed the expression of PKC-beta in 33% of tumors. "
4.	Macular Edema 01/01/2007 - "Ongoing prospective clinical trials investigate whether the treatment with the specific PKC-beta inhibitor can prevent the progression of diabetic retinopathy and diabetic macular edema." 11/01/2002 - "Ongoing clinical studies investigate if the treatment with specific PKC-beta inhibitors can prevent the progression of diabetic retinopathy and diabetic macular edema." 03/01/2011 - "To review current data regarding protein Kinase C beta (PKCß) inhibitors and its efficacy in reducing the burden of diabetic retinopathy (DR) and diabetic macular edema (DME). " 12/01/2002 - "The potential role of PKC beta in diabetic retinopathy and macular edema." 01/01/2007 - "Positive results from the PKC Beta Inhibitor Diabetic Macular Edema (PKC-DMES) trial were reported in 2003. "
5.	Diabetes Complications 05/01/2006 - "Currently, clinical trials are in progress to determine the efficacy of a PKC beta inhibitor for the treatment of diabetic complications including DN. " 12/01/2003 - "Phase III clinical trials on the safety and the preventive effects of the PKC-beta-specific inhibitor on diabetic complications are under progress. " 06/01/1998 - "Clinical studies are now in progress to determine whether PKC-beta inhibition can prevent diabetic complications." 01/01/2002 - "The ability of isoform-specific PKC inhibitors to antagonize diabetes-induced abnormalities has implicated altered PKC beta activity in the onset of several diabetic complications, In contrast to many other tissues, DAG levels fall in diabetic nerve and a consistent pattern of change in PKC activity has not been observed. " 08/25/2010 - "Protein kinase C-beta (PKC-beta) is a cell-signaling intermediate implicated in development of diabetic complications. "

Related Drugs and Biologics

1.	ruboxistaurin
2.	Protein Kinase C beta
3.	Protein Isoforms (Isoforms)
4.	Protein Kinase C
5.	Proteins (Proteins, Gene)
6.	Messenger RNA (mRNA)
7.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
8.	Carcinogens
9.	(2R)- 3- (2- aminomethyl- 2,3- dihydro- 1H- 3a- azacyclopenta(a)inden- 8- yl)- 4- phenylaminopyrrole- 2,5- dione monomethanesulphonate
10.	dimethylethylsilylimidazole

Related Therapies and Procedures

1.	Therapeutics
2.	Vitrectomy
3.	Radiotherapy
4.	Drug Therapy (Chemotherapy)
5.	Transplantation